In the FDA drug approval process, priority review accelerates the evaluation timeline for therapies addressing serious conditions or offering significant improvements over existing options. This designation shortens the review goal to six months, compared to the standard ten. Patients with unmet medical needs benefit most, gaining faster access to groundbreaking treatments for cancer, rare diseases, and other life-threatening illnesses.
Get alerts when this topic surges in newsletters. Free to start.
Sign up freeExplore more trends:Trending Topics ·AI Trends ·Business Trends ·Finance Trends ·Technology Trends